|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 185,800.00 KRW | +1.98% |
|
+3.97% | +7.78% |
| 12:49am | Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma | MT |
| 07-24 | Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55 | MT |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Neutral |
| Resistance | 190,000 | 236,667 | 230,476 |
| Spread/Res. | -2.21% | -21.49% | -19.38% |
| Spread/Supp. | +5.69% | +16.56% | +16.40% |
| Support | 175,800 | 159,400 | 159,619 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- A068270 Stock
- Charts Celltrion, Inc.
Select your edition
All financial news and data tailored to specific country editions
